Pediatric Sweet Syndrome and Immunodeficiency Successfully Treated with Intravenous Immunoglobulin
Article first published online: 23 NOV 2005
Volume 22, Issue 6, pages 530–535, November 2005
How to Cite
Haliasos, E., Soder, B., Rubenstein, D. S., Henderson, W. and Morrell, D. S. (2005), Pediatric Sweet Syndrome and Immunodeficiency Successfully Treated with Intravenous Immunoglobulin. Pediatric Dermatology, 22: 530–535. doi: 10.1111/j.1525-1470.2005.00133.x
- Issue published online: 23 NOV 2005
- Article first published online: 23 NOV 2005
Abstract: Painful erythematous plaques and a pathognomonic, dense, dermal infiltrate of neutrophils characterize Sweet syndrome. Although numerous instances of this disease have been reported in children, only four have had an associated immunodeficiency to date. Sweet syndrome has been traditionally treated with systemic corticosteroids despite an unknown pathogenesis. Prior reports suggest that immunodeficient children with Sweet syndrome may have a persistent course and fail to respond to standard treatment. We describe a child with debilitating Sweet syndrome and a primary immunodeficiency whose symptoms were controlled with intravenous immunoglobulin and dapsone.